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The GTPase Rab11 plays key roles in receptor recycling, oogenesis, autophagosome forma-
tion, and ciliogenesis. However, investigating Rab11 regulation has been hindered by limited
molecular detail describing activation by cognate guanine nucleotide exchange factors
(GEFs). Here, we present the structure of Rab11 bound to the GEF SH3BP5, along with
detailed characterization of Rab-GEF specificity. The structure of SH3BP5 shows a coiled-coil
architecture that mediates exchange through a unique Rab-GEF interaction. Furthermore, it
reveals a rearrangement of the switch I region of Rab11 compared with solved Rab-GEF
structures, with a constrained conformation when bound to SH3BP5. Mutation of switch I
provides insights into the molecular determinants that allow for Rab11 selectivity over evo-
lutionarily similar Rab GTPases present on Rab11-positive organelles. Moreover, we show that
GEF-deficient mutants of SH3BP5 show greatly decreased Rab11 activation in cellular assays
of active Rab11. Overall, our results give molecular insight into Rab11 regulation, and how Rab-
GEF specificity is achieved.
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Critical to almost all aspects of membrane trafficking andcellular signaling is the ability to properly traffic mem-brane cargoes. Cells possess a highly regulated system for
directing membrane cargo to the proper cellular location, with
one of the key determinants being the regulation of Rab (Ras
related proteins in brain) GTPases1–4. Rab proteins mediate
specific exchange of proteins and lipid cargos between distinct
intracellular organelles, through selective binding and recruit-
ment of Rab-binding proteins. Thus, Rabs are crucial to proper
cellular function and their dysregulation leads to a variety of
disease states.
Rab GTPases act as molecular switches and cycle between a
GDP “off” state and a GTP-bound “on” state. They are lipidated
at the C terminus, with geranylgeranyl modifications of C-
terminal cysteines mediating their membrane association. Human
Rab proteins show a remarkable diversity, with over 66 identified
members, of which at least 20 were present in the last common
ancestor of all Eukaryotes5. The association of Rab-binding part-
ners is specific to the nucleotide-bound state, with most Rab
effectors having specificity for the GTP-bound active conforma-
tion. A majority of Rab GTPases have extremely low intrinsic rates
of nucleotide exchange and GTP hydrolysis and require regulatory
proteins to control their spatiotemporal activation and inactiva-
tion. The nucleotide-binding state of Rab GTPases is regulated
through the coordinated interplay of activating guanine nucleotide
exchange factors (GEFs) and inactivating GTPase-activating pro-
teins (GAPs), with an additional level of control mediated by
guanine nucleotide dissociation inhibitory proteins6–9.
Among the best studied Rab GTPases are members of the
Rab11 subfamily, which in humans comprised three isoforms
(Rab11A, Rab11B, and Rab25 [also known as Rab11C]). The
Rab11 proteins are master regulators of the surface expression of
receptors10. They are primarily localized at the trans-Golgi net-
work, post-Golgi vesicles, and the recycling endosome, and they
facilitate cytokinesis11, ciliogenesis12, oogenesis13, and neur-
itogenesis14. Intriguingly, Rab11-positive vesicles have also been
identified as precursors for autophagosome assembly15, which is
one of the initiating steps of autophagy. Both Rab11A and
Rab11B are mutated in developmental disorders, with putative
inactivating Rab11A or Rab11B mutations leading to intellectual
disability and brain malformation16,17. Overexpression of Rab25
has been implicated in poor prognosis in ovarian cancer, with
stapled peptide inhibitors of Rab25-effector binding inhibiting
migration and proliferation18,19. Many intracellular pathogens,
including viruses20, bacteria21, and parasites22 subvert membrane
trafficking through targeting Rab11-positive vesicles.
Hindering the capability to fully understand Rab11 regulation
is the lack of molecular detail describing how Rab11 proteins are
activated by their cognate GEFs. Biochemical reconstitution of the
large macromolecular TRAPPII complex with their cognate
Rab11 homologs in both yeast (Saccharomyces cerevisiae) and
fruit flies (Drosophila melanogaster) revealed clear GEF activity
toward both Rab1 (yeast Ypt1) and Rab11 (yeast Ypt31/32)23,24.
The Drosophila DENN protein Crag was also identified as a GEF
toward both Rab10 and Rab1125. Neither of these GEFs is
selective for Rab11, with both Rab10 and Rab1 having a different
spatial organization compared with Rab11, implying the existence
of other more specific Rab11 GEFs.
The first insight into potentially Rab11-specific GEF proteins
was the discovery of the protein REI-1 and its homolog REI-2 in
Caenorhabditis elegans, with loss of both leading to defects in
cytokinesis26. These enzymes are found only in metazoans, and
knockouts of the REI-1 ortholog in Drosophila (parcas, also
known as poirot) are viable but have defects in oogenesis and
muscle development27–29. Intriguingly, knockouts of either
TRAPPII or parcas are viable in Drosophila but the double
knockout is embryonic lethal, suggesting the shared GEF activity
for Rab11 is partially redundant23. The mammalian ortholog of
REI-1, SH3-binding protein 5 (SH3BP5), also has GEF activity
toward Rab11 and was shown to be selective for Rab11 over
Rab526. In addition, mammals contain a SH3BP5 homolog,
SH3BP5L, which has not yet been tested for Rab11 GEF activity.
The role of SH3BP5 in development and signaling is complicated
by its additional capability to directly regulate Bruton tyrosine
kinase (BTK) signaling through binding to the BTK SH3
domain30, as well as to inhibit JNK signaling through engagement
of the disordered C terminus of SH3BP531,32.
The fundamental molecular mechanism by which Rab11 pro-
teins can be activated by their cognate GEFs has remained
unclear. To decipher the mechanism of SH3BP5 GEF activity we
have determined the structure of the GEF domain of SH3BP5
bound to nucleotide-free Rab11A. Detailed biochemical studies
reveal that SH3BP5 is highly selective for Rab11 isoforms, with no
activity toward any of the most evolutionarily similar Rab
GTPases. A subset of clinical Rab11 mutations found in devel-
opmental disorders were found to disrupt SH3BP5-mediated
nucleotide exchange, providing a possible mechanism of disease.
Detailed mutational analysis of both Rab11 and SH3BP5 reveals
the molecular basis for Rab selectivity, as well as allowing for the
design of GEF-deficient SH3BP5 mutants. These SH3BP5
mutants were tested using a cellular Rab11 fluorescence reso-
nance energy transfer (FRET) sensor and show significantly
decreased Rab11 activation. Overall, our study thus reveals insight
into Rab11 regulation and defines how Rab11-GEF selectivity is
achieved.
Results
Biochemical characterization of SH3BP5 GEF activity. SH3BP5
was previously demonstrated to act as a GEF for Rab1126 and this
activity was strongly dependent on the membrane presentation of
Rab11. To examine the specificity of GEF activity for Rab11
family members, GEF assays were carried out on the Rab11
isoforms Rab11A and Rab25 loaded with the fluorescent GDP
analog 3-(N-methyl-anthraniloyl)-2-deoxy-GDP (Mant-GDP)
and nucleotide exchange was determined as a function of
SH3BP5 concentration. Rab11 proteins were generated with a C-
terminal His-tag, which allows for localization on NiNTA-
containing membranes (Fig. 1a). Domain schematics of all pur-
ified protein constructs generated in this study are shown in
Supplementary Figure 1.
The catalytic efficiency of SH3BP5 GEF activity (kcat/Km) was
highest for Rab11A, ~3.5 × 104 M−1 s−1, with slightly lower
values for Rab25 (11c) at ~1.8 × 104 M−1 s−1 (Fig. 1b). SH3BP5L
GEF activity was even higher, with values of ~8.1 × 104 M−1 s−1
against Rab11A. Measurements of SH3BP5 Rab GEF activity were
characterized both in solution and in a membrane-reconstituted
system where Rab isoforms were attached to NiNTA-containing
membrane using a C-terminal His-tag, similar to previous Rab11
GEF studies on the Drosophila and yeast variants of the TRAPPII
complex23,24. SH3BP5 GEF activity showed only a weak
dependence on Rab11A being present on a lipid membrane, with
a ~2-fold higher rate on a membrane compared with free in
solution, consistent with biochemical studies performed on the
Drosophila homolog parcas23.
Previously, Rab11 activation has been associated with
the generation of different phosphoinositides, including
phosphatidylinositol-3-phosphate (PI3P) and L-α-phosphatidyli-
nositol-4-phosphate (PI4P)33–35. To test this biochemically, GEF
assays were carried out on vesicles of both different size (100 nm
and 400 nm) and different membrane composition including
variations of surface charge and phosphoinositide (PS, PI, PI3P,
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and PI4P) composition (Supplementary Figure 2a). There was no
difference in membrane-stimulated GEF activity across all
membranes tested (Supplementary Figure 2b). Rab GEF-
mediated nucleotide exchange has also been previously shown
to have a strong dependence on dominant active switch II
mutants36 (Q70L in Rab11). However, GEF assays on Q70L
Rab11A showed a slightly elevated GEF-mediated nucleotide
exchange rate for Q70L compared with wild-type (WT) Rab11A
(Supplementary Figure 2d). The dominant negative mutant of
Rab11A (S25N) caused rapid release of Mant-GDP even in the
absence of SH3BP5 (Supplementary Figure 2d).
SH3BP5 has been found to be selective for Rab11 over Rab526.
However, these GTPases are highly evolutionarily distinct. To
define the selectivity of SH3BP5 for Rab11, we characterized the
GEF activity of SH3BP5 toward the most evolutionarily similar
Rab GTPases (Rab2A, Rab4B, Rab14, and Rab12)5 as well as
Rab8, which is activated downstream of a Rab11-dependent Rab
cascade12. SH3BP5 showed no detectable Rab GEF activity for
any of these Rab GTPases at up to 300 nM concentration of GEF,
revealing that SH3BP5 is both a highly potent and highly selective
Rab11 GEF (Fig. 1f).
Structure and dynamics of the Rab11A–SH3BP5 complex. To
define the dynamics of the full-length SH3BP5 protein, we used
hydrogen deuterium exchange mass spectrometry (HDX-MS).
HDX-MS measures the exchange rate of amide hydrogens with
solvent, and as the main determinant of exchange is the stability
of secondary structure, it is an excellent probe of secondary
structure dynamics37. HDX experiments with extremely short
exposures of D2O can be used to identify disordered regions
within proteins38. We carried out HDX experiments with a short
pulse of deuterium exposure (3 s at 1 °C) for the full-length
SH3BP5, with both the N terminus and C terminus of SH3BP5
having > 50% deuterium incorporation, indicating limited sec-
ondary structure (Supplementary Figure 3a). HDX-MS results
were used to generate a crystal construct of SH3BP5, with all of
the C-terminal disordered region removed (SH3BP5 1–265). GEF
assays carried out using either full-length SH3BP5, a N-terminally
truncated (31–455) version, and the 1–265 crystal construct
revealed no difference in SH3BP5-mediated Rab11A nucleotide
exchange, suggesting that the disordered N and C termini have no
effect on Rab11 binding or SH3BP5 GEF activity (Supplementary
Figure 3c, d). The complex of the crystal construct of SH3BP5
(1–265) and Rab11A Q70L was able to be purified to homo-
geneity and eluted as a 1:1 complex on gel filtration (Supple-
mentary Figure 3e, f).
To understand the molecular basis of how SH3BP5 mediates
Rab11A nucleotide exchange, we determined the structure of the
N-terminal GEF domain of SH3BP5 bound to full-length Q70L
Rab11A to a final resolution of 3.1 Å. The Q70L construct of
Rab11 was used for structural studies as the marginally increased
GEF rate for Q70L vs. WT suggested Q70L might form a slightly
more stable complex with SH3BP5. Initial phases were generated
by SeMet single wavelength anomalous diffraction of 3.3 Å and
extended to 3.1 Å using native data (Fig. 2, details on unit cell
data collection and refinement details are in Supplementary
Figure 4 and Table 1). The structure is composed of four
complexes of SH3BP5-Rab11A per asymmetric unit, with each of
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Fig. 1 In vitro GEF assays reveal that SH3BP5 is a potent and selective GEF for Rab11. a Schematic of GEF activation assays using fluorescent analog Mant-
GDP in the presence and absence of NiNTA-containing lipid vesicles. b In vitro GEF assay of SH3BP5 (1–455) on Rab11A and Rab25, and SH3BP5L (1–393)
on Rab11A. Nucleotide exchange was monitored by measuring the fluorescent signal during the SH3BP5(1–455) (9 nM-300 nM) catalyzed release of
Mant-GDP from 4 µM of Rab11a-His6 in the presence of 100 µM GTPγS. Each concentration was conducted in triplicate. c Calculation of kcat/Km values for
nucleotide exchange rates of Rab11A (SH3BP5 and SH3BP5L) and Rab25 (SH3BP5) according to the protocol of ref. 61. d In vitro GEF assay of SH3BP5 on
Rab11A in the presence and absence of 100 nm extruded liposomes at 0.2 mg/ml (10% DGS-NTA(Ni), 10% PS, 15% PE, 20% PI, 45% PC). Nucleotide
exchange was monitored by measuring the fluorescent signal during the SH3BP5 (1–455) (26 nM)-catalyzed release of Mant-GDP from 4 µM of Rab11A-
His6 in the presence of 100 µMGTPγS. e Bar graph representing the difference in GEF activity in the presence and absence of Ni-NTA membranes. f In vitro
GEF assays of SH3BP5 against a panel of evolutionarily related Rab GTPases loaded with Mant-GDP at a final concentration of 300 nM SH3BP5 and 4 µM
Rab GTPase. For all panels, error bars represent SD (n= 3), with p-values generated using a two-tailed Student’s t-test (***p < 0.005)
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the copies in the asymmetric unit sharing an overall similar
architecture. The following structural analysis refers to the
complex of SH3BP5 chain E and Rab11A chain F, as this
complex showed the best-defined electron density. The GEF
domain of SH3BP5 is composed of a coiled coil that is kinked to
form an overall v-shape. The v is composed of four long α-helices
(α1–α4), with a small helix connecting helices α2 α3. This
connecting region between helix α2 α3 shows the highest degree
of conformational flexibility between copies in the asymmetric
unit (Supplementary Figure 4). The putative SH3-binding site for
BTK is located at the turn from helix α3 to α430. However, this
region shares no similarity to any previously identified SH3-
binding site. A surface potential map of SH3BP5 reveals limited
highly charged regions, with one basic stretch located at the base
of the v shape (Supplementary Figure 4). There also are no
putative amphipathic helices in SH3BP5 that would potentially
mediate membrane binding. The N-terminal GEF domain of
SH3BP5 was previously predicted to share homology to F-bar
domains26. However, bioinformatic analysis using the DALI
server revealed that the closest structural homologs are the cell
invasion protein SipB (PDB: 3tul [https://www.rcsb.org/structure/
3tul]), the stalk region of dynein (PDB: 5ayh [https://www.rcsb.
org/structure/5ayh]), and the bacterial chaperone prefoldin (PDB:
1fxk [https://www.rcsb.org/structure/1fxk]). The highest similar-
ity to the α1/α4 Rab11 binding coiled coil is the archaeal
chaperone prefoldin39. The characteristic v-shape of SH3BP5,
however, is unique among solved coiled-coil proteins.
Nucleotide-free Rab11A was bound to the GEF domain of
SH3BP5 at one end of the v at a surface composed of the N
terminus of helix α1 and the C terminus of helix α4 of the coiled
coil. The SH3BP5-Rab11 interface is composed of a large
extended, primarily hydrophobic interface (~1250 Å2) (Fig. 3a).
The Rab11-binding surface of SH3BP5 is composed of residues
39–67 and residues 240–262. The contact residues at this interface
are highly conserved both in SH3BP5 and SH3BP5L, as well as
the parcas and REI-1/2 homologs in both Drosophila and C.
elegans, respectively (Fig. 3b). The SH3BP5-binding surface of
Rab11 is composed of residues spanning the N terminus (residues
6–13), residues in and near switch I (residues 35–48), the inter-
switch region 58–65, residues in and near switch II (72–85), and
the C terminus (180–181). Rab11 packs along the center of the
coiled coil of SH3BP5, with the main binding interface composed
of a contiguous hydrophobic surface of Rab11 residues including
Y8, L10, and Y11 at the N terminus, F36 and I44 in switch I, Y73
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Fig. 2 Structure of SH3BP5 in complex with Nucleotide-free Rab11. a Schematic of full-length SH3BP5(1–455), the crystal construct of SH3BP5 (1–265) and
Rab11A with switch I (SwI) and switch II (SwII) regions annotated. b The structure of the GEF domain of SH3BP5 with nucleotide-free Rab11 solved to 3.1 Å
resolution. The GEF domain of SH3BP5 is composed of a v-shaped coiled coil with four long α-helices annotated on the figure. The switch regions of Rab11
are colored yellow (Switch I (SwI)) and orange (switch II (swII)), with the SwI situated between helix α1 and α4 of SH3BP5
Table 1 Data collection and refinement statistics
SH3BP5-Rab11
native
SH3BP5-Rab11 SeMet
(peak)
Data collection
Space group I222 I222
Cell dimensions
a, b, c (Å) 114.85, 197.04,
304.71
114.13, 197.18, 304.20
α, β, γ (°) 90, 90, 90 90, 90, 90
Resolution (Å) 49.26–3.10
(3.21–3.10)a
49.39–3.25 (3.36–3.25)
Rmerge 0.1363 (2.189) 0.156 (2.214)
I / σI 8.26 (0.75) 13.68 (1.35)
Completeness (%) 99.74 (99.79) 99.88 (99.72)
Redundancy 4.9 (5.1) 13.2 (13.0)
Refinement
Resolution (Å) 49.26–3.1 (3.21– 3.1)
No. reflections 62,902 (6236)
Rwork / Rfree 23.5/27.8
No. atoms
Protein 12,888
Ligand/ion 0
Water 0
B-factors
Protein 132.44
Ligand/ion
Water
R.m.s. deviations
Bond lengths (Å) 0.003
Bond angles (°) 0.55
aValues in parentheses are for highest-resolution shell.
Number of crystals used for structure= 1
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and I76 in switch II, and the hydrophobic triad (F48, W65, and
Y80), which has a conserved role in interacting with Rab
effectors40 (Fig. 3c).
HDX-MS experiments were carried out to both verify the
crystallographic complex as well as define how SH3BP5 works on
a membrane surface. HDX-MS experiments revealed differences
in exchange for Rab11A Q70L when bound to a N-terminally
truncated SH3BP5 (31–455), with decreased HDX at the SH3BP5
interface (Supplementary Figure 5a–c), verifying the crystal-
lographic interface in solution. Increased exchange was observed
surrounding the Rab11 nucelotide-binding pocket and this likely
corresponds to loss of nucleotide upon SH3BP5 binding. HDX-
MS experiments mapping out the Rab11 interface for the N-
terminally truncated variant of SH3BP5 (31–455) were carried
out with both soluble and membrane localized WT Rab11A
(1–211, C-term his) to analyze conformational changes that may
occur upon membrane binding. Decreases in exchange were
observed for SH3BP5 at the crystallographic interface with
Rab11A, with the only consequence of membrane being a larger
decrease in exchange in Rab11A interfacial residues in SH3BP5
(Supplementary Figure 5d–f) and no additional regions showing
changes in H/D exchange. This potentially signifies a tighter
interaction between SH3BP5 and Rab11A occurring on a
membrane surface, which might possibly explain the limited
selectivity of SH3BP5 for different membrane compositions
(Supplementary Figure 2).
Comparison with previously solved Rab-GEF complexes.
Comparison of the structure of nucleotide-free Rab11A bound to
SH3BP5 compared with Rab11A bound to either GDP or GTP
reveals an extensive rearrangement of switch I41, with only lim-
ited conformational changes in switch II (Fig. 4a and Supple-
mentary Figure 6, Supplementary Movie 1). One of the minor
conformational changes that occurs in switch II upon SH3BP5
binding is a reorientation of Y73, where the hydroxyl group is in
position to cap the switch I helix (S40-G45). There were also
conformational changes that occurred around the nucleotide-
binding pocket, including decreased secondary structure,
although not to the same extent as seen in the Rab8:MSS4 GEF
complex42. HDX-MS studies of differences between nucleotide-
bound Rab11 and SH3BP5-bound nucleotide-free Rab11 showed
large increases in exchange in all regions of Rab11 around
the nucleotide-binding pocket when bound to SH3BP5
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Fig. 3 Rab11A SH3BP5 interface. a Zoom in on the binding interface of Rab11 and SH3BP5. Key Rab11 residues forming important interactions at the
interface are labeled. b Alignment of the Rab11-binding site on both helix α1 and α4 of SH3BP5 and SH3BP5L along with paralogs from M. musculus
(mSH3BP5), D. melanogaster (parcas), and C. elegans (REI-1/REI-2), with contact residues indicated by arrows. Red arrows indicate greater than 20 Å2 of
buried surface area (BSA). c All interacting residues from both SH3BP5 and Rab11 are shown in stick representation and labeled, with the structures rotated
and the interacting partner removed to allow for visualization. SwI and SwII are colored according to Fig. 2
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(Supplementary Figure 5a–c), further highlighting decreased
stability of the nucleotide-binding pocket.
The substantial conformational change of switch I upon
SH3BP5 binding is present in all previously solved Rab-GEF
structures and is predicted to mediate nucleotide exchange
through disrupting switch I nucleotide interactions. However,
comparison of the conformational change in switch I reveals
striking differences between previously solved Rab-GEF struc-
tures. The main difference is in the conformation of F36 and I44
in Rab11. These residues pack directly against each other, which
requires a constrained conformation of switch I. This constrained
orientation of the highly conserved F36 and I44 residues (Fig. 4a,
b) is unique compared with previously solved Rab-GEF
structures. There are a number of similarities with previously
solved GEF structures, with a helix forming from S40 to G45 in
switch I of Rab11, similar to DENND1B-Rab3543 and Mon1-
Ccz1-Ypt744 structures. Lysine 41 in Rab11 when bound to
SH3BP5 is oriented toward the empty Mg2+-binding site;
however, there was limited electron density around this residue,
indicating that it is quite flexible (Supplementary Figure 4). This
same lysine residue in Ypt7 has a key role in activation by Mon1-
Ccz144, with the mechanism proposed to be mediated through
disruption of the Mg2+-binding site.
Individual point mutations in Rab11A (K13N, K24R, R82C,
and S154L) and Rab11B (V22M and A68T) are found in
developmental disorders that lead to intellectual disability16,17.
Mapping these mutations onto the structures of nucleotide-
bound Rab11, Rab11-GTPγS bound to the Rab11 effector FIP3,
and SH3BP5-Rab11 revealed possible roles of these mutations in
Rab11 regulation (Fig. 5, Supplementary Figure 7). The V22M
and S154L would be expected to sterically disrupt nucleotide-
binding and HDX-MS experiments of these mutants compared
with WT Rab11 revealed large increases in exchange throughout
the entire Rab protein (Supplementary Figure 7), indicating that
indeed these mutants are not able to bind nucleotide. No GEF
assays were able to be carried out on these mutants, as they could
not be loaded with Mant-GDP. K24R is part of the P-loop that
coordinates the phosphate groups in bound nucleotide and GEF
assays revealed that this mutant had rapid nucleotide exchange
even in the absence of SH3BP5 (Fig. 5), indicating decreased
affinity for nucleotide. HDX-MS experiments on this mutant
revealed increased exchange throughout the majority of Rab11,
although not as large as changes seen for V22M and S154L
(Supplementary Figure 7). The A68T mutant is located at the
beginning of switch II, with the Ala oriented toward the region of
switch II that interacts with SH3BP5, and it only showed a modest
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effect in decreasing SH3BP5-mediated GEF activity. K13N and
R82C are located directly at the Rab11-SH3BP5 interface, with R82
forming a salt bridge with E50 in SH3BP5 and K13 forming a polar
bond with Q53 in SH3BP5. The K13 residue also forms pi-stacking
interaction with the hydrophobic triad residue W65, which directly
binds to SH3BP5. Mutation of K13N resulted in a > 100-fold
decrease in SH3BP5-mediated GEF activity, with R82 only partially
decreasing SH3BP5 GEF activity (Fig. 5). However, these mutations
are unlikely to modify only GEF activity, as the R82 residue also
forms a salt bridge with E747 in FIP345.
The discovery that the SH3BP5 coiled coil acts as a GEF
suggested that it may act similarly to the previously structurally
characterized coiled coil Sec2p GEF Sec4p (Rab8 and Rabin8 in
humans)46,47. Surprisingly, the SH3BP5 coiled coil is perpendi-
cular to the Sec2p coiled coil (Fig. 4c) and the two Rab GEFs
interact with completely divergent binding surfaces on their
cognate Rabs. Intriguingly, this suggests independent evolution of
coiled coils to act as GEFs toward Rab GTPases.
Defining the molecular basis of SH3BP5 Rab11 selectivity. To
further understand how SH3BP5 is able to achieve selectivity for
Rab11 over evolutionarily similar Rab GTPases, we carried out site-
directed mutagenesis of switch I residues in Rab11. We tested the
role of F36 and I44 residues, with mutation of these residues to
Alanine leading to almost completely abrogated SH3BP5-mediated
GEF activity (Fig. 6a-c). Mutations in switch I that mimic residues
found in Rab2A (L38P), Rab8 (S40F), and Rab14 (K41P) were also
found to decrease GEF activity > 100-fold, with limited effect on
intrinsic nucleotide exchange (Fig. 6a, b). These residues would all
be predicted to disrupt the constrained conformation of F36 and
I44 relative to each other, leading to disruption of the contiguous
hydrophobic surface required for interaction with SH3BP5. Muta-
tion of these residues to Ala, also greatly decreased GEF activity. In
Ypt7, the yeast homolog of Rab7, K41 has a key role in mediating
GEF activity through insertion into the Mg2+-binding site. To
determine whether this was conserved in Rab11, we tested GEF
activity of a K41A Rab11 mutant. This led to a relatively minor ~3-
fold decrease in GEF activity, compared with the previously
reported 10-fold decrease in GEF activity for Mon1-Ccz1 on the
K38A mutant of Ypt744. This suggests that the role of this lysine
residue in inserting into the Mg2+-binding site is less important in
SH3BP5-mediated GEF activity on Rab11 compared with Mon1-
Ccz1-mediated GEF activity toward Ypt7.
Generation of SH3BP5 GEF-deficient mutations. Critical to
understanding the role of SH3BP5 is to define differences
between its BTK/JNK regulatory roles and Rab11 regulatory roles,
which requires the generation of point mutations that disrupt
only specific SH3BP5 functions. From examining the structure of
SH3BP5 bound to Rab11 and sequence conservation throughout
evolution, we separately mutated Rab11 contact interfaces in helix
α1 (LNQ52AAA) and α4 (LE250AK) of SH3BP5. To ensure the
protein was properly folded, we used HDX-MS to test con-
formational dynamics. Both mutants showed increased exchange
only at the Rab11 interface, with no global changes in deuterium
incorporation (Supplementary Figure 7g), suggesting these
mutants remain properly folded. Both mutants led to a > 100-fold
decrease in GEF activity compared with WT SH3BP5 (Fig. 6d, e).
To study activation of Rab11 in a cellular context, we used a
recently developed Rab11 activation sensor (AS-Rab11)33. AS-
Rab11 is composed of the Rab-binding domain (RBD) of FIP3,
monomeric yellow fluorescent protein (mcpVenus), a proteinase
K-sensitive linker, a monomeric cyan fluorescent protein, and
human Rab11A (Fig. 7a). The RBD of FIP3 is specific to GTP-
bound Rab11, with the consequence being that in the absence of
active Rab11 there is low FRET and upon Rab11 activation the
FRET signal increases. This was verified using AS-Rab11 mutants,
both active Rab11 (AS-Rab11 Q70L) and inactive Rab11 (AS-
Rab11 S25N), with increased FRET levels for Q70L, and
decreased FRET for S25N (Supplementary Figure 8).
Immunofluorescence of FLAG-tagged SH3BP5 revealed an
intracellular membrane distribution (Fig. 7b-d) similar to the AS-
Rab11 sensor (Fig. 7c). Although SH3BP5wt showed an important
colocalization with both total Rab11 and active Rab11 (Fig. 7d, e,
Supplementary Figure 8B), the two GEF mutants SH3BP5AAA
and SH3BP5AK displayed lower colocalization with active Rab11
(Fig. 7d, e). Accordingly, transfection of SH3BP5 led to increased
Rab11 activation, which was not observed with transfection of the
GEF-deficient mutants, confirming that these mutations disrupt
Rab11 activation by SH3BP5 in living cells and cell lysates
(Fig. 7f, Supplementary Figure 8c, d).
Discussion
Rab11 GTPases are essential mediators of numerous membrane-
trafficking processes and are especially important in controlling
receptor recycling. Most Rab11-dependent processes have been
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Fig. 5 Clinically relevant Rab11 mutations disrupt nucleotide-binding or alter SH3BP5 GEF activity. a Point mutations found in developmental disorders
mapped on the structure of Rab11 bound to SH3BP5. b In vitro GEF assay of SH3BP5 on clinical Rab11 mutations. Nucleotide exchange was monitored by
measuring the fluorescent signal during the SH3BP5 (1–455) (300 nM, 150 nM, or 75 nM) catalyzed release of Mant-GDP from 4 µM of the indicated Rab
in the presence of 100 µM GTPγS. Fluorescent measurements were completed every 11 s for a total of 60min (Excitation λ= 366 nm; Emission λ= 443
nm). c Nucleotide exchange rates of Rab11A mutants plotted as a function of SH3BP5 concentration. The kcat/Km values for all Rab11A mutations were
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NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06196-z ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3772 | DOI: 10.1038/s41467-018-06196-z | www.nature.com/naturecommunications 7
studied through the use of dominant active (Q70L) and dominant
inactive (S25N) mutants. These mutations can lead to misleading
results, as many Rab GTPases are activated by GEFs through
direct interactions with the catalytic Gln residue36, leading to
impaired activation for GTPase-deficient mutants. Complicating
the ability to fully probe Rab11 and its role in both fundamental
biological processes and disease has been the lack of molecular
detail for the coordinated action of Rab11 GEFs and GAPs.
Multiple Rab11 GAPs have been identified, including the proteins
TBC1D1148, TBC1D1549, and EVI550,51. Similarly, multiple
Rab11 GEFs have been characterized, with the yeast and Droso-
phila TRAPPII complex activating both Rab1 and Rab1123,24, and
the Drosophila DENN family protein Crag being identified as a
weak activator of Rab11, with a much higher activity towards
Rab1025. SH3BP5, which is conserved in C. elegans, is a potent
Rab11 GEF26 and knockout of the Drosophila homolog parcas
leads to defects in oogenesis27. Intriguingly, it has been shown
that Rab11 has a key role in oogenesis, through mediating
asymmetric cell division13, revealing a potential role of SH3BP5
in Rab11 regulation.
The structure of SH3BP5 bound to Rab11 reveals that the
extended coiled coil of the GEF domain forms an extended pre-
dominantly hydrophobic interface with Rab11. The catalytic
efficiency of SH3BP5L (~8.1 × 104 M−1 s−1) and SH3BP5 (~3.5 ×
104 M−1 s−1) is comparable to previously determined Rab GEFs,
including the Mon1-Ccz1 complex (∼2.1 × 104 M−1 s−1)44,
DENND1 (~2.9 × 104 M−1 s−1)43, and the TRAPP complex
(~1.6 × 104 M−1 s−1)52. There was a slight activation of SH3BP5
when Rab11 was presented on a membrane surface, with no
strong dependency on surface charge, or phosphoinositide
0 1000 2000 3000 4000
0.0
0.5
1.0
0 1000 2000 3000 4000
0.0
0.5
1.0
0.0
0.5
1.0
0 1000 2000 3000 4000
0.0
0.5
1.0
N
or
m
al
iz
ed
 fl
uo
re
sc
en
ce
Mock
300 nM SH3BP5
Mock
300 nM SH3BP5
Mock
300 nM SH3BP5
Mock
300 nM SH3BP5
Rab11a (L38P)
Rab11a (K41A)
Rab11a (S40F)
Rab11a (K41P)
0 1000 2000 3000 4000
0.0
0.5
1.0
Time (s)
N
or
m
al
iz
ed
 fl
uo
re
sc
en
ce
1 μM
LE250AK
1 μM
LNQ52AAA
52 nM
WT
Mock
0
5
10
15
20
25
Rab11a(S40F)
2.9±0.1×102 M–1 s–1
0 100 200 300
0
5
10
15
nM SH3BP5
Rab11a
3.5±0.1×104 M–1 s–1
Rab11a(K41A)
1.1±0.1×104 M–1 s–1
Rab11a(K41P)
0.5±0.1×102 M–1 s–1
Rab11a(L38P)
5.7±0.1×102 M–1 s–1
0 1000 2000 3000 4000
0.0
0.5
1.0
N
or
m
al
iz
ed
 fl
uo
re
sc
en
ce
Rab11a (L38A)
Mock
300 nM SH3BP5
0 1000 2000 3000 4000
0.0
0.5
1.0
Time (s)
Mock
300 nM SH3BP5
Rab11a (S40A)
0 1000 2000 3000 4000
0.0
0.5
1.0
0 1000 2000 3000 4000
0 1000 2000 3000 4000
0.0
0.5
1.0
Time (s)
Mock
300 nM SH3BP5
Mock
300 nM SH3BP5
Rab11a (I44A)
Rab11a (F36A)
0 100 200 300
0
5
10
15
nM SH3BP5
Rab11a(S40A)
4.4±0.1×103 M–1 s–1
Rab11a
3.5±0.1×104 M–1 s–1
Rab11a(L38A)
1.8±0.1×104 M–1 s–1
Rab11a(F36A)
3.1±0.1×102 M–1 s–1
Rab11a(I44A)
0.5±0.1×102 M–1 s–1
Time (s) Time (s)
0 1000 2000 3000 4000
0.0
0.5
1.0
Time (s)
N
or
m
al
iz
ed
 fl
uo
re
sc
en
ce
k o
bs
 
(s–
1 ) 
× 1
0–
3Rab11a (WT)
Mock
300 nM SH3BP5
L38
I44
K41
S40
F36
LE250AK
LNQ52AAA
SH3BP5 SwI
Ex
ch
an
ge
 ra
te
10
–
3 
μM
–
1 
s–
1
a
b
c d e
WT
LN
Q5
2A
AA
LE
25
0A
K
Fig. 6 Molecular basis of SH3BP5 specificity and generation of GEF-deficient mutants. a In vitro GEF assay of SH3BP5 on Switch I Rab11 mutations.
Nucleotide exchange was monitored by measuring the fluorescent signal during the SH3BP5 (1–455) (300 nM) catalyzed release of Mant-GDP from 4 µM
of the indicated Rab in the presence of 100 µM GTPγS. Fluorescent measurements were completed every 11 s for a total of 60min (Excitation λ= 366 nm;
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content. Rab11 activation has been found to be associated with
different phosphoinositide species, including PI4P during cytokin-
esis35 and PI3P in ciliogenesis34. One of the main ways that Rab
proteins are localized is through targeting of GEFs to specific
intracellular membranes, and further experiments will be needed to
define if SH3BP5 is involved in phosphoinositide-dependent acti-
vation, potentially through localization to specific phosphoinositide-
containing organelles by protein-binding partners.
Active Rab11 mediates its roles in membrane trafficking through
recruiting a number of protein-binding partners, including motor
protein complexes, and the exocyst complex53. Rab11 is also unique
among Rab GTPases in that it can interact with the protein-binding
partners PI4KB54 and Rabin855 through a unique interface directly
over the nucleotide-binding pocket, which allows for the formation
of tertiary complexes with Rab11 effectors. PI4KB can bind GDP-
bound Rab1138, suggesting there might be a role in GEF pre-
sentation. However, the structure of Rab11 bound to SH3BP5
precludes formation of a ternary complex with PI4KB.
The structure of SH3BP5 bound to Rab11 reveals the
mechanism for how SH3BP5 binding leads to nucleotide
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Fig. 7 Cellular assays of Rab11 activation. a Schematic of activation sensor Rab11 (AS-Rab11)33. Upon activation by GEF proteins, GTP-loaded Rab11 will bind
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exchange and Rab11 specificity (Fig. 8). Switch I residues have a
key role in stabilizing bund nucleotide, with F36 and L38 forming
a hydrophobic cap over the guanine ring in both GDP- and GTP-
bound structures41. In the SH3BP5-bound complex there is a
substantial conformational change in switch I of Rab11 compared
with nucleotide-bound states, which leads to disruption of switch
I nucleotide contacts and allows for release of bound nucleotide.
Specifically, F36 and L38 undergo an extensive rearrangement to
interact with SH3BP5 and this disrupts their ability to interact
with bound nucleotide. Mutation of either F36 or L38 to alanine
surprisingly does not lead to a large increase in the intrinsic
exchange rate, as seen for the corresponding F33 in Ypt7
(equivalent to F36 in Rab11)44; however, mutation of F36 to
alanine prevents SH3BP5-mediated nucleotide exchange. The
disruption of the interaction of the aromatic residue located in
SwI with nucleotide has a key role in nucleotide exchange in
TRAPP52 and DENND143, and this is conserved in SH3BP5. The
large conformational change in switch I is characteristic of pre-
viously solved Rab-GEF structures42–44,46,47,52,56. The SH3BP5
coiled coil that interacts with Rab11 shares the closest structural
homology to the coiled coil archaeal chaperone prefoldin39, and
this ability to stabilize partially unfolded proteins reveals a
potential evolutionary path to stabilizing the partially unfolded
Rab11 nucleotide-free state.
SH3BP5 is highly selective for Rab11 and this is likely driven
through a highly constrained conformation of the hydrophobic
residues F36 and I44 in switch I. This makes Rab11 extremely
sensitive to mutation of switch I residues between F36 and I44,
which prevent this constrained F36-I44 orientation. The K41 in
switch I projects into the Mg2+-binding pocket, similar to seen in
the Ypt7-Mon1-Ccz1 complex44. However, mutation of this
residue in Rab11 leads to only a minor decrease in GEF efficiency,
with this suggesting it does not play as critical a role as for Ypt7-
Mon1-Ccz1. Rab11A and Rab11B are mutated in developmental
disorders16,17, leading to encephalopathies and co-occurrence of
seizures and intellectual disability. The V22M, S154L, and K24R
all destabilized Rab11, either through a complete (V22M, S154L)
or partial (K24R) disruption of nucleotide binding. K13N almost
completely prevented SH3BP5-mediated nucleotide exchange,
with R82C and A68T both leading to slightly decreased rates.
This reveals that clinically relevant Rab11 mutations disrupt
SH3BP5-mediated exchange.
The use of a genetically encoded Rab11 FRET sensor33 revealed
that transfection of SH3BP5 leads to a significant increase in
Rab11 activation, with no increase seen with SH3BP5 GEF-
deficient mutations. Fluorescently labeled SH3BP5 and AS-Rab11
colocalize, with SH3BP5 primarily localizing to intracellular
membranes. Among the key unanswered questions are the
mechanisms by which SH3BP5 is localized to specific intracellular
membranes and whether SH3BP5 is required for activation of a
specific Rab11 pool. As SH3BP5 has key roles in regulation of the
signaling kinases BTK and JNK through a non-GEF-mediated
process, the molecular details presented here provide an approach
to define the roles of SH3BP5 in Rab11-dependent processes.
Misregulation of Rab11 isoforms is a key driver in oncogenesis
(Rab25) and developmental diseases (Rab11A and Rab11B), and
our work reveals insight into how Rab11 can be activated.
Moreover, our results not only reveal the specifics of Rab11-GEF
activation but also provide important insight into the mechan-
isms by which Rab GEFs achieve specificity.
Methods
Plasmids and antibodies. The full-length SH3BP5 gene was provided by MGC
(DanaFarber HsCD00326538 [https://plasmid.med.harvard.edu/PLASMID/
GetCloneDetail.do?cloneid= 326538&species= ]). pDONR223-SH3BP5(31-455)
was a gift from William Hahn and David Root (Addgene plasmid #23579 [https://
www.addgene.org/23579/]). Rab25 (HsCD00327861 [https://plasmid.med.harvard.
edu/PLASMID/GetCloneDetail.do?cloneid= 327861&species= ]), SH3BP5L
(HsCD00323009 [https://plasmid.med.harvard.edu/PLASMID/GetCloneDetail.do?
cloneid= 323009&species= ]), Rab8a (HsCD00044586 [https://plasmid.med.
harvard.edu/PLASMID/GetCloneDetail.do?cloneid= 44586&species= ]), Rab4b
(HsCD00296539 [https://plasmid.med.harvard.edu/PLASMID/GetCloneDetail.do?
cloneid= 296539&species= ]), Rab2a (HsCD00383517 [https://plasmid.med.
harvard.edu/PLASMID/GetCloneDetail.do?cloneid= 383517&species= ]), Rab14
(HsCD00322387 [https://plasmid.med.harvard.edu/PLASMID/GetCloneDetail.do?
cloneid= 322387&species= ]), and Rab12 (HsCD00297182 [https://plasmid.med.
harvard.edu/PLASMID/GetCloneDetail.do?cloneid= 297182&species= ]) were
purchased from the Dana Farber Plasmid Repository. Genes were subcloned into
vectors containing a N-terminal GST-tag and, in some cases, a C-terminal His-tag
by Gibson assembly. Rab11 and SH3BP5 substitution mutations were generated
using site-directed mutagenesis according to published protocols, and C-terminal
and N-terminal residues of SH3BP5 were removed using Gibson ligation-
independent assembly57. The following antibodies were used in this study: rabbit
anti-SH3BP5 (SIGMA, HPA057988, IF 1:50) and anti-rabbit IgG Alexa Fluor 568
(ThermoFisher, A-11036, IF 1:1000).
Bioinformatics. Sequences were aligned using Clustal Omega Multiple Sequence
Alignment and the aligned sequences were subsequently analyzed by ESPript 3.0 to
visualize conserved regions. The protein interaction interfaces from the asymmetric
unit was examined using the PDBePISA (Proteins, Interfaces, Structures and
Assemblies) server58. The SH3BP5 structure was compared with similar PDB
structures using the DALI server59. The surface potential map was generated using
the APBS server60.
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Protein expression. Constructs of SH3BP5 and Rab11 were all expressed in BL21
C41 Escherichia coli. Rab11 was induced with 0.5 mM IPTG (isopropyl β-D-1-
thiogalactopyranoside) and grown at 37 °C for 4 h. Rab25 was expressed in Rosetta
cells, induced with 0.1 mM IPTG and grown overnight at 23 °C. SH3BP5 and the
remaining Rab proteins were induced with 0.1 mM IPTG and grown overnight at
23 °C. SeMet Rab11 and SH3BP5 were expressed in B834 E. coli in minimal media
with SeMet (Molecular Dimensions), induced with 0.1 mM IPTG, and grown
overnight at 23 °C. Pellets were washed with ice-cold phosphate-buffered saline,
flash frozen in liquid nitrogen, and stored at − 80 °C until use.
Protein purification. Cell pellets were lysed by sonication for 5 min in lysis buffer
(20 mM Tris pH 8.0, 100 mM NaCl, 2 mM β-mercaptoethanol (BME), and pro-
tease inhibitors (Millipore Protease Inhibitor Cocktail Set III, Animal-Free)). Tri-
ton X-100 was added to 0.1% v/v and the solution was centrifuged for 45 min at
20,000 × g at 1 °C. Supernatant was loaded onto a 5 ml GSTrap 4B column (GE) in
a superloop for 2 h and the column was washed in Buffer A (20 mM Tris pH 8.0,
100 mM NaCl, 2 mM BME) to remove nonspecifically bound proteins. The GST-
tag was cleaved by adding Buffer A containing 10 mM BME and TEV protease to
the column and incubating overnight at 4 °C. Cleaved protein was eluted with
Buffer A. Protein was further purified by separating on a 5 ml HiTrap Q column
with a gradient of Buffer A and Buffer B (20 mM Tris pH 8.0, 1 M NaCl, 2 mM
BME). Protein was pooled and concentrated using Amicon 30 K concentrator and
size exclusion chromatography (SEC) was performed using a Superdex 200 increase
10/300 or Superdex 75 10/300 column equilibrated in SEC Buffer (20 mM HEPES
pH 7.5, 500 mM NaCl, 0.5 mM TCEP). Rab proteins not used for crystallography
were purified using SEC Buffer 2 (20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM
MgCl2, and 0.5 mM TCEP). Fractions containing protein of interest were pooled,
concentrated, flash frozen in liquid nitrogen, and stored at − 80 °C.
Protein for crystallization was generated through mixing the SH3BP5
truncations and Rab11(Q70L) described above at an equimolar amount. The
protein mixture was incubated for 5 min at 4 °C. EDTA (pH 7.5) was added to a
final concentration of 20 mM and the solution was left to incubate for 1 h at 4 °C.
The protein complex was centrifuged for 3 min at 21,130 × g and loaded onto a
Superdex 200 10/300 column to separate the complex from free nucleotide.
Fractions containing protein of interest were pooled, concentrated, flash frozen in
liquid nitrogen and stored at − 80 °C.
Lipid vesicle preparation. Nickelated lipid vesicles were made to mimic the
composition of the Golgi organelle [15% phospatidylethanolamine (egg yolk PE,
Sigma), 20% phosphatidylinositol (soybean PI from Avanti), 10% phosphati-
dylserine (bovine brain PS, Sigma), 45% phosphatidylcholine (egg yolk PC Sigma),
and 10% DGS-NTA(Ni) (18:1 DGSNTA(Ni), Avanti)]. All other vesicle compo-
sitions are described in Supplementary Figure 2. PI3P and PI4P were obtained from
Avanti. Vesicles were prepared by combining liquid chloroform stocks together at
appropriate concentrations and evaporating away the chloroform with nitrogen
gas. The resulting lipid film layer was desiccated for 20 min before being resus-
pended in lipid buffer (20 mM HEPES (pH 7.5) and 100 mM KCl) to a con-
centration of 2.0 mg/mL or 1 mg/ml. The lipid solution was vortexed for 5 min,
bath sonicated for 10 min, and flash frozen in liquid nitrogen. Vesicles were then
subjected to three freeze thaw cycles using a warm water bath. Vesicles were
extruded 11 times through a 100 nm NanoSizer Liposome Extruder (T&T Scien-
tific) or a 400 nm NanoSizer Liposome Extruder (T&T Scientific) and stored at −
80 °C.
In-vitro GEF assay. C-terminally His-tagged Rab11 was purified as described
above. Rab11 was preloaded for the assay by adding EDTA to a final concentration
of 5 mM and incubating for 30 mins prior to adding fivefold excess of Mant-GDP
(ThermoFisher Scientific). Magnesium chloride was added to 10 mM to terminate
the loading process and the solution was incubated for 30 min at 25 °C. SEC was
performed using a Superdex 75 10/300 column in SEC Buffer 2 (20 mM HEPES pH
7.5, 150 mM NaCl, and 1 mM MgCl2, 0.5 mM TCEP) to remove any unbound
nucleotide. Fractions containing Mant-GDP loaded Rab11 were pooled, con-
centrated, flash frozen in liquid nitrogen, and stored at − 80 °C. Reactions were
conducted in 10 µl volumes with a final concentration of 4 µM Mant-GDP loaded
Rab11, 100uM GTPγS, and SH3BP5(9nM-1µM) or SH3BP5L. Rab11 and mem-
brane (0.2–0.4 mg/ml, see Supplementary Figure 2) were aliquoted into a 384-well,
black, low-volume plate (Corning 3676). To start the reaction, SH3BP5 and GTPγS
were added simultaneously to the wells and a SpectraMax® M5 Multi-Mode
Microplate Reader was used to measure the fluorescent signal for 1 h (Excitation λ
= 366 nm; Emission λ= 443 nm). Data was analyzed using GraphPad Prism 7
Software, and kcat/Km analysis was carried out according to the protocol of ref. 61.
In brief, GEF curves were fit to a non-linear dissociate one phase exponential decay
using the formula I(t)= (I0− I∞)*exp(− kobs*)+ I∞ (GraphPad Software), where I
(t) is the emission intensity as a function of time, and I0 and I∞ are the emission
intensities at t= o and t=∞. The catalytic efficiency kcat/Km was obtained by a
slope of a linear least squares fit to kobs= kcat/Km*[GEF]+ kintr, where kintr is the
rate constant in the absence of GEF.
Crystallography. Crystallization trials of the SH3BP5-Rab11 complex were set
using a Crystal Gryphon liquid handling robot (Art Robbins Instruments) in 96-
well Intelli-Plates using sitting drops at 18 °C. Initial hits were obtained in the
Index HT crystallization kit (Hampton Research) and refinement plates for Index
HT condition F11 (25% (w/v) PEG-3350, 200 mM sodium chloride, 100 mM Bis-
Tris pH 6.5) were set. The best crystals of the optimized SH3BP5 construct with
Rab11A were obtained in 2 μL hanging drops, with a reservoir solution of 23% (w/
v) PEG-3350, 200 mM sodium chloride, 100 mM Bis-Tris pH 6.5, with a ratio of 4:1
protein/reservoir. Crystals were frozen in liquid nitrogen using cryo buffer [24%
PEG-3350 (w/v), 200 mM sodium chloride, 100 mM Bis-Tris pH 6.5, 15% (v/v)
ethylene glycol]. SeMet containing crystals were obtained in 1.6 μL hanging drops
with a reservoir solution of 14% (w/v) PEG-3350, 200 mM NaBr, 100 mM Bis-Tris
pH 5.5, and 5% Tacsimate pH 6.0 at a ratio of 4:1 protein to reservoir. Crystals
were frozen in liquid nitrogen using cryo buffer 2 [20% (w/v) PEG-3350, 150 mM
NaCl, 50 mM NaBr, 100 mM Bis-Tris pH 5.5, 5% Tacsimate pH 6.0, and 15% (v/v)
ethylene glycol].
Diffraction data were collected at 100 K at beamline 08ID-1 of the Canadian
Macromolecular Crystallography Facility (Canadian Light Source). Native data
were collected at a wavelength of 0.97949 Ã and SeMet data was collected at
0.97895 Ã. Data were integrated using XDS62 and scaled with AIMLESS63. Datasets
were collected for both native SH3BP5 (1–265)/Rab11 (1–213) and SeMet
incorporated SH3BP5 (1–265)/Rab11 (1–213). Full crystal collection details are
shown in Table 1. Initial phases were determined by single-wavelength anomalous
dispersion at the selenium peak energy with initial phases, density modification and
automated model building carried out using CRANK (version 2.0)64. This allowed
for an initial model of SH3BP5 to be build and the location of Rab11 was identified
in the asymmetric unit through molecular replacement using PHASER65, with the
structure of GDP-bound Rab11 used as the search model with both switch I and
switch II removed41. The final model of SH3BP5-Rab11 complex was built using
iterative model building, including manual rebuilding of the Rab11 switches in
COOT66 and refinement using phenix.refine67 to a Rwork= 23.54 and Rfree= 27.80.
Ramachandran statistics for final model—favored 96.6%, outliers 0.51%. Full
crystallographic statistics are shown in Table 1.
Identification of disordered regions in SH3BP5 using HDX-MS. HDX reactions
were conducted in 50 µl reaction volumes with a final concentration of 0.2 µM
SH3BP5 (1–455) per sample. Exchange was carried out in triplicate for a single
time point (3 s at 1 °C) and all steps were carried out in a 4 °C cold room.
Hydrogen deuterium exchange was initiated by the addition of 48 µl of D2O buffer
solution (10 mM HEPES pH 7.5, 50 mM NaCl, 97% D2O) to the protein solution,
to give a final concentration of 93% D2O. Exchange was terminated by the addition
of acidic quench buffer at a final concentration 0.6 M guanidine-HCl and 0.9%
formic acid. Samples were immediately frozen in liquid nitrogen at -80 °C.
Mapping changes in Rab11 mutants using HDX-MS. All clinically relevant
Rab11 mutants were purified identically to WT Rab11. HDX reactions were con-
ducted in 50 µl reaction volumes with a final concentration of 0.5 µM Rab11(WT,
V22M, K24R, or S154L) per sample. Exchange was carried out in triplicate for two
time points: 3 s at 1 °C and 300 s at 18 °C. Hydrogen deuterium exchange was
initiated by the addition of 49 µl of D2O buffer solution (10 mM HEPES (pH 7.5),
50 mM NaCl, 97% D2O) to the protein solution, to give a final concentration of
95% D2O. Exchange was terminated by the addition of acidic quench buffer at a
final concentration 0.6 M guanidine-HCl and 0.9% formic acid. Samples were
immediately frozen in liquid nitrogen at − 80 °C.
Mapping of the SH3BP5-Rab11-binding interface using HDX-MS. HDX reac-
tions were conducted in 20 µl reaction volumes with a final concentration of 1.0 µM
Rab11(Q70L) and 1.0 µM SH3BP5 (31–455) per sample. Exchange was carried out
in triplicate for four time points (3 s at 1 °C and 3 s, 30 s and 300 s at room
temperature). Before the addition of D2O, both proteins were incubated on ice in
the presence of 20 µM EDTA for 1 h to facilitate release of nucleotide. Hydrogen
deuterium exchange was initiated by the addition of 17.5 µl of D2O buffer solution
(10 mM HEPES pH 7.5, 500 mM NaCl, 97% D2O) to 2.5 µl of the protein solutions,
to give a final concentration of 78% D2O. Exchange was terminated by the addition
of acidic quench buffer at a final concentration 0.6 M guanidine-HCl and 0.9%
formic acid. Samples were immediately frozen in liquid nitrogen at − 80 °C.
Investigating the role of membrane using HDX-MS. HDX reactions were con-
ducted in 20 µl reaction volumes with a final concentration of 0.4 µM C-terminally
His-tagged Rab11A (1–211), 0.4 µM SH3BP5 (31–455), and 0.2mg/mL nickelated
lipid vesicles [15% PE, 20% PI, 10% PS, 45% PC, and 10% DGS-NTA(Ni)] per
sample. Exchange was carried out in triplicate for four time points (3 s, 30 s, 300 s,
3000 s) at room temperature. Before the addition of D2O, 1 µl of 20 µM Rab11 and
2 µl of 2 mg/mL membrane (or membrane buffer) were left to incubate for 30 s. One
microliter of 20 µM SH3BP5 was then added and incubated a further 30 s prior to
the initiation of hydrogen deuterium exchange by the addition of 16 µl of D2O
buffer solution (10mM HEPES pH 7.5, 200mM NaCl, 97% D2O) to the samples to
give a final concentration of 77% D2O. Exchange was terminated by the addition of
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acidic quench buffer giving a final concentration 0.6M guanidine-HCl and 0.9%
formic acid. Samples were immediately frozen in liquid nitrogen at -80 °C.
Mutational analysis of SH3BP5 using HDX-MS. HDX reactions were conducted
in 50 µl reaction volumes with a final concentration of 0.6 µM SH3BP5(WT) or 0.6
µM SH3BP5(LNQ52AAA), or 0.6 µM SH3BP5(LE250AK) per sample. Exchange
was carried out in triplicate for two time points (3 s, 300 s at 18 °C). Hydrogen
deuterium exchange was initiated by the addition of 48.5 µl of D2O buffer solution
(10 mM HEPES pH 7.5, 200 mM NaCl, 97% D2O) to the samples to give a final
concentration of 94% D2O. Exchange was terminated by the addition of acidic
quench buffer giving a final concentration 0.6 M guanidine-HCl and 0.9% formic
acid. Samples were immediately frozen in liquid nitrogen at − 80 °C.
HDX-MS data analysis. Protein samples were rapidly thawed and injected onto an
ultra-performance liquid chromatography (UPLC) system kept in a cold box at 2 °
C. The protein was run over two immobilized pepsin columns (Applied Biosys-
tems; Porosyme 2-3131-00) and the peptides were collected onto a VanGuard
Precolumn trap (Waters). The trap was eluted in line with an ACQUITY 1.7 μm
particle, 100 × 1 mm2 C18 UPLC column (Waters), using a gradient of 5%-36% B
(Buffer A 0.1% formic acid, Buffer B 100% acetonitrile) over 16 min. MS experi-
ments were performed on an Impact QTOF (Bruker) and peptide identification
was done by running tandem MS (MS/MS) experiments run in data-dependent
acquisition mode. The resulting MS/MS datasets were analyzed using PEAKS7
(PEAKS) and a false discovery rate was set at 1% using a database of purified
proteins and known contaminants. HDExaminer Software (Sierra Analytics) was
used to automatically calculate the level of deuterium incorporation into each
peptide. All peptides were manually inspected for correct charge state and presence
of overlapping peptides. Deuteration levels were calculated using the centroid of
the experimental isotope clusters. Fully deuterated samples were generated by
incubating SH3BP5 with 3M guanidine for 30 min before the addition of D2O. The
protein was exchanged for 1 h on ice before adding quench buffer. This fully
deuterated sample allows for the control of peptide back exchange levels during
digestion and separation. Differences in exchange were in a peptide were con-
sidered significant if they met all three of the following criteria: > 5% change in
exchange, > 0.5 Da difference in exchange, and a p-value < 0.01 using a two-tailed
Student’s t-test. Samples were only compared within a single experiment and were
never compared with experiments completed at a different time with a different
final D2O level.
Rab11 activated sensor cellular experiments. HEK 293 T cells (2 × 105; ATCC,
CRL-11268) were plated in a six-well plate and Lipofectamine 2000 (Invitrogen)
was used for transfection. Less than 500 ng of DNA were transfected in every
condition. After 36 h of transfection, lysis was performed in lysis buffer (50 mM
Tris-HCl, pH 7.4, 1% Tritorn X-100, 10 mM MgCl2, 100 mM NaCl, proteinase
inhibitors) and lysate was measured in a fluorometer cuvette. The Fluoromax-4
Horiba fluorometer was used to perform the measure. Laser excitation at 433 nm
was used and the emission spectrum from 450 to 550 nm was recorded. A second
measurement was made by directly exciting YFP at 505 nm and measuring its
emission at 525 nm, to normalize for biosensor concentration. Colocalization
analysis was performed using ImageJ JACOP plugin. Pearson’s coefficient of cor-
relation was calculated using Costes’ automatic threshold.
Quantification of Rab11 activity in COS-7 cells. The sensitized FRET and CFP
images acquired from transfected COS-7 cells (ATCC, CRL-165), were smoothed
using Gaussian blur and background subtraction was performed according to
previous published protocol68. Afterwards, FRET activity ratio was computed by
dividing sensitized FRET pixels by the CFP pixels, excluding saturated signals.
Statistical analysis. Six independent experiments (n) were performed for
microscopy-based experiments, and statistical significance were obtained. Means ±
SEM were used to present values. P-values were calculated using one-way analysis
of variance followed by Bonferroni’s multiple comparison post test (GraphPad
Software). The following legends are used for statistical significance: *P < 0.05, **P
< 0.01, and ***P < 0.005.
For all GEF and HDX-MS assays, experiments were carried out in triplicate and
means ± SD are shown in all figures. Statistical analysis between conditions was
performed using a two-tailed Student’s t-test, with p-values shown the same as
described for cellular experiments.
Data availability
The structure factors and coordinates for the structure of Rab11A bound to SH3BP5 have
been deposited in the protein databank with the accession code 6DJL. The mass spec-
trometry proteomics data have been deposited to the ProteomeXchange Consortium via
the PRIDE69 partner repository with the dataset identifier PXD010586. The processed
HDX-MS data are provided as Supplementary Data 1. All other data supporting the
findings of this study are available from the corresponding author on reasonable request.
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